Inogen’s (INGN) “Hold” Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their hold rating on shares of Inogen (NASDAQ:INGN) in a research note issued to investors on Tuesday morning,Benzinga reports.

Separately, StockNews.com lowered shares of Inogen from a “buy” rating to a “hold” rating in a research note on Friday, December 20th.

Inogen Price Performance

NASDAQ INGN opened at $10.52 on Tuesday. Inogen has a one year low of $5.08 and a one year high of $13.33. The firm has a market cap of $250.59 million, a P/E ratio of -4.68 and a beta of 1.02. The stock’s 50-day moving average is $9.54 and its 200-day moving average is $9.91.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Quarry LP acquired a new stake in Inogen in the 3rd quarter valued at approximately $59,000. Verition Fund Management LLC acquired a new stake in shares of Inogen in the third quarter valued at approximately $106,000. Virtu Financial LLC bought a new stake in shares of Inogen in the third quarter worth $111,000. Paloma Partners Management Co acquired a new position in Inogen during the third quarter worth $126,000. Finally, Centiva Capital LP bought a new position in Inogen in the third quarter valued at $138,000. 89.94% of the stock is owned by institutional investors and hedge funds.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.